AbstractTapentadol may have a lower abuse risk than other opioids because it has a relatively low affinity for the mu-opioid receptor. The aim of this retrospective cohort study was to compare the risk of opioid abuse between tapentadol immediate release (IR) and oxycodone IR using 2 claims databases (Optum and MarketScan). Subjects with no recent opioid use exposed to tapentadol IR or oxycodone IR in 2010 were followed for 1 year. The outcome was the proportion of subjects who developed opioid abuse, defined as subjects with International Classification of Diseases, 9th revision, codes for opioid abuse, addiction, or dependence. The relative odds of abuse were estimated using a logistic regression model with propensity-score stratification...
Aims: A new oxycodone formulation (Reformulated OxyContin® was released in Australia, early 2014. It...
Background: Evaluation of tamper resistant formulations (TRFs) and classwide Risk Evaluation and Mit...
2019 Elsevier B.V. Aims: A sustained-release formulation (SRF) of tapentadol has been marketed in Au...
AbstractTapentadol may have a lower abuse risk than other opioids because it has a relatively low af...
Objectives: This study compared the risks of opioid shopping behavior and opioid abuse between tapen...
AbstractObtaining opioids from multiple prescribers, known as doctor shopping, is 1 example of opioi...
Aim: To establish and quantify the association between abuse-deterrent formulation (ADF) oxycodone a...
Tapentadol, a Schedule II opioid with a combination of µ-opioid activity and norepinephrine reuptake...
Background: The rapid increase in prescribing and use of opioids for noncancer pain has coincided wi...
Introduction: Opioid medications have been increasingly prescribed in recent years, particularly to ...
Background: Escalation of pharmaceutical opioid use and harm in North America is well-documented, wi...
<p><b>Objectives</b>: There is an epidemic of nonmedical and extra-medical use opioid abuse, addicti...
BACKGROUND: Non-medical use and abuse of prescription opioids is a significant problem in the Unite...
It is estimated that nearly a third of people who abuse drugs started with prescription opioid medic...
Controlled-release opioid formulations may have differential abuse liability profiles related to rat...
Aims: A new oxycodone formulation (Reformulated OxyContin® was released in Australia, early 2014. It...
Background: Evaluation of tamper resistant formulations (TRFs) and classwide Risk Evaluation and Mit...
2019 Elsevier B.V. Aims: A sustained-release formulation (SRF) of tapentadol has been marketed in Au...
AbstractTapentadol may have a lower abuse risk than other opioids because it has a relatively low af...
Objectives: This study compared the risks of opioid shopping behavior and opioid abuse between tapen...
AbstractObtaining opioids from multiple prescribers, known as doctor shopping, is 1 example of opioi...
Aim: To establish and quantify the association between abuse-deterrent formulation (ADF) oxycodone a...
Tapentadol, a Schedule II opioid with a combination of µ-opioid activity and norepinephrine reuptake...
Background: The rapid increase in prescribing and use of opioids for noncancer pain has coincided wi...
Introduction: Opioid medications have been increasingly prescribed in recent years, particularly to ...
Background: Escalation of pharmaceutical opioid use and harm in North America is well-documented, wi...
<p><b>Objectives</b>: There is an epidemic of nonmedical and extra-medical use opioid abuse, addicti...
BACKGROUND: Non-medical use and abuse of prescription opioids is a significant problem in the Unite...
It is estimated that nearly a third of people who abuse drugs started with prescription opioid medic...
Controlled-release opioid formulations may have differential abuse liability profiles related to rat...
Aims: A new oxycodone formulation (Reformulated OxyContin® was released in Australia, early 2014. It...
Background: Evaluation of tamper resistant formulations (TRFs) and classwide Risk Evaluation and Mit...
2019 Elsevier B.V. Aims: A sustained-release formulation (SRF) of tapentadol has been marketed in Au...